The US Food and Drug Administration has cleared a major regulatory hurdle standing between the Department of Transportation and the adoption of oral fluid drug testing for commercial drivers, according to TheTrucker.com.

The action, described in the original headline as a "major hurdle" cleared, moves DOT one step closer to authorizing saliva-based specimen collection as part of the mandatory drug testing panel for interstate truck and bus operators.

What does this change for drivers and carriers?

For decades, the DOT drug and alcohol testing regime for commercial drivers has rested on urine-based specimen collection. Oral fluid testing, which detects drug metabolites in saliva, has been pitched by lab operators and equipment makers as faster to administer, harder to adulterate, and easier to observe at the point of collection.

The trucking industry has tracked the methodology shift closely. The DOT Drug and Alcohol Clearinghouse — the federal database that records positive, refused and other reportable tests — has reshaped how carriers screen and monitor CDL holders since coming online in 2020. Faster collection, proponents argue, would compress the time a driver spends off the road during pre-employment, random, post-accident and return-to-duty testing events.

How does this connect to the freight market?

The trucking sector continues to manage tight driver supply, and anything that shortens out-of-service time for a CDL holder has a direct, if incremental, effect on available capacity. Recruiters and safety directors have flagged specimen collection delays as a chronic source of friction, particularly at high-volume collection sites that serve multiple carriers from a single location.

If oral fluid testing shrinks the window between a test order and a result, fleets gain a faster pipeline from applicant to seat, and from a return-to-duty event back to a behind-the-wheel driver. The economic value of that speed compounds across an industry that hires, terminates and re-hires at scale.

What still has to happen?

An FDA action on the testing platform does not by itself authorize DOT to use oral fluid in federally mandated testing. The Department of Transportation must still amend its drug-testing regulations to permit the methodology, and laboratories must be certified under whatever framework the agency adopts.

Until those regulatory steps land, urine-based testing remains the operational default for any DOT-covered driver.

How should shippers, brokers and 3PLs read this?

For now, the change is regulatory rather than commercial. Spot rates, contract lane economics and tender rejection levels will not move on the news alone. But the underlying signal — federal regulators actively working to reduce friction in the commercial driver pipeline — is consistent with the broader policy direction that has emphasized trucking workforce capacity across multiple administrations.

Carriers that have already invested in oral fluid collection infrastructure at their in-house clinics may find themselves ahead of competitors once DOT publishes a final rule. Watch the Federal Register for the next filing from the DOT Office of Drug and Alcohol Policy and Compliance.

TheTrucker.com's reporting indicates the FDA's action is the latest step in a multi-year rulemaking process that, if completed, would mark the first material change to federal commercial driver specimen collection in a generation.